| Page (NASDAQ: PRPO) A Cancer Diagnostics Solutions Company 2022 Corporate Presentation DISCLAIMER This presentation has been prepared by Precipio Inc.(the “Company”) and is general background information about the Company’s activities as of the date of this presentation. By accepting this presentation, the recipient acknowledges and agrees that all of the information contained herein is confidential, that the recipient will distribute, disclose, and use such information only for such purpose and that the recipient shall not distribute, disclose or use such information in any way detrimental to the Company. The information contained herein does not purport to be all inclusive and the Company nor any of its respective affiliates nor any of its or their controlling persons, officers, directors, employees or representatives makes any representation or warranty, express or implied, as to the accuracy, completeness or reliability of the information contained in this presentation. This presentation does not contain all the information that is or may be material to investors or potential investors and should not be considered as advice or a recommendation to investors or potential investors in respect of the holding, purchasing or selling of securities or other financial instruments and does not take into account any investor’s particular objectives, financial situation or needs. Certain statements in this presentation may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any anticipated/forecasted results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management’s current views and estimates of future economic circumstances, industry conditions, company performance, financial results, including the ability of the company to increase its presence/impact/market share in the diagnostic products and services markets, and regulatory matters. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by the Company and its management, as the case may be, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in the Company’s filings with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-Q and 10-K. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management’s control including general economic conditions and other risks, as well as factors associated with companies, such as Precipio, that are engaged in diagnostics and other research and development activities in the biotechnology industry, including uncertainty in product acceptance and/or receipt of regulatory approvals for product candidates, including any delays and other impacts from the COVID 19 pandemic. Accordingly, the Company claims the protection of the safe harbour for forward-looking statements contained in the Securities Act with respect to all statements contained in this presentation. All information in this presentation is as of the date when this presentation was provided to the recipient by Precipio and Precipio does not undertake any duty to update this information, including any forward-looking statements, unless required by law. No representation or warranty, express or implied, is made as to the fairness, accuracy or completeness of the presentation and the information contained herein and no reliance should be placed on it. Information in this presentation (including market data and statistical information) has been obtained from various sources (including third-party sources) and the Company does not guarantee the accuracy or completeness of such information. While the Company believes its internal research is reliable, such research has not been verified by any independent source. All projections, valuations and statistical analyses are provided for information purposes only. The contents of this presentation should not be considered to be legal, tax, investment or other advice, and any investor or prospective investor considering the purchase or disposal of any securities of the Company should consult with its own counsel and advisers as to all legal, tax, regulatory, financial and related matters concerning an investment in or disposal of such securities and as to their suitability for such investor or prospective investor This presentation and its contents are confidential and proprietary to the Company, and no part of it or its subject matter may be reproduced, redistributed, passed on, or the contents otherwise divulged, directly or indirectly, to any other person (excluding the relevant person’s professional advisers) or published in whole or in part for any purpose without the prior written consent of the Company. 1 Rev. 2022 - 06 |
